496 related articles for article (PubMed ID: 10933923)
1. The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis.
Meng RD; McDonald ER; Sheikh MS; Fornace AJ; El-Deiry WS
Mol Ther; 2000 Feb; 1(2):130-44. PubMed ID: 10933923
[TBL] [Abstract][Full Text] [Related]
2. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha.
Sheikh MS; Burns TF; Huang Y; Wu GS; Amundson S; Brooks KS; Fornace AJ; el-Deiry WS
Cancer Res; 1998 Apr; 58(8):1593-8. PubMed ID: 9563466
[TBL] [Abstract][Full Text] [Related]
3. The antiapoptotic decoy receptor TRID/TRAIL-R3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract.
Sheikh MS; Huang Y; Fernandez-Salas EA; El-Deiry WS; Friess H; Amundson S; Yin J; Meltzer SJ; Holbrook NJ; Fornace AJ
Oncogene; 1999 Jul; 18(28):4153-9. PubMed ID: 10435597
[TBL] [Abstract][Full Text] [Related]
4. Molecular determinants of response to TRAIL in killing of normal and cancer cells.
Kim K; Fisher MJ; Xu SQ; el-Deiry WS
Clin Cancer Res; 2000 Feb; 6(2):335-46. PubMed ID: 10690508
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.
Mérino D; Lalaoui N; Morizot A; Schneider P; Solary E; Micheau O
Mol Cell Biol; 2006 Oct; 26(19):7046-55. PubMed ID: 16980609
[TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 2 (DcR2) is a p53 target gene and regulates chemosensitivity.
Liu X; Yue P; Khuri FR; Sun SY
Cancer Res; 2005 Oct; 65(20):9169-75. PubMed ID: 16230375
[TBL] [Abstract][Full Text] [Related]
7. Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation.
van Noesel MM; van Bezouw S; Salomons GS; Voûte PA; Pieters R; Baylin SB; Herman JG; Versteeg R
Cancer Res; 2002 Apr; 62(7):2157-61. PubMed ID: 11929838
[TBL] [Abstract][Full Text] [Related]
8. Death and decoy receptors and p53-mediated apoptosis.
Sheikh MS; Fornace AJ
Leukemia; 2000 Aug; 14(8):1509-13. PubMed ID: 10942251
[TBL] [Abstract][Full Text] [Related]
9. Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma.
Zhang XD; Franco A; Myers K; Gray C; Nguyen T; Hersey P
Cancer Res; 1999 Jun; 59(11):2747-53. PubMed ID: 10364001
[TBL] [Abstract][Full Text] [Related]
10. Requirement of p53 targets in chemosensitization of colonic carcinoma to death ligand therapy.
Wang S; El-Deiry WS
Proc Natl Acad Sci U S A; 2003 Dec; 100(25):15095-100. PubMed ID: 14645705
[TBL] [Abstract][Full Text] [Related]
11. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells.
Sanlioglu AD; Dirice E; Aydin C; Erin N; Koksoy S; Sanlioglu S
BMC Cancer; 2005 May; 5():54. PubMed ID: 15916713
[TBL] [Abstract][Full Text] [Related]
12. p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma.
Meng RD; El-Deiry WS
Exp Cell Res; 2001 Jan; 262(2):154-69. PubMed ID: 11139340
[TBL] [Abstract][Full Text] [Related]
13. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene.
Guan B; Yue P; Clayman GL; Sun SY
J Cell Physiol; 2001 Jul; 188(1):98-105. PubMed ID: 11382926
[TBL] [Abstract][Full Text] [Related]
15. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells.
Zhang XD; Franco AV; Nguyen T; Gray CP; Hersey P
J Immunol; 2000 Apr; 164(8):3961-70. PubMed ID: 10754286
[TBL] [Abstract][Full Text] [Related]
16. P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells.
Toscano F; Fajoui ZE; Gay F; Lalaoui N; Parmentier B; Chayvialle JA; Scoazec JY; Micheau O; Abello J; Saurin JC
Oncogene; 2008 Jul; 27(30):4161-71. PubMed ID: 18345033
[TBL] [Abstract][Full Text] [Related]
17. Preparation and characterization of a set of monoclonal antibodies to TRAIL and TRAIL receptors DR4, DR5, DcR1, and DcR2.
Liu XS; Zhu Y; Han WN; Li YN; Chen LH; Jia W; Song CJ; Liu F; Yang K; Li Q; Jin BQ
Hybrid Hybridomics; 2003 Apr; 22(2):121-5. PubMed ID: 12831538
[TBL] [Abstract][Full Text] [Related]
18. Control of apoptosis signaling by Apo2 ligand.
Marsters SA; Pitti RA; Sheridan JP; Ashkenazi A
Recent Prog Horm Res; 1999; 54():225-34. PubMed ID: 10548878
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types.
Shivapurkar N; Toyooka S; Toyooka KO; Reddy J; Miyajima K; Suzuki M; Shigematsu H; Takahashi T; Parikh G; Pass HI; Chaudhary PM; Gazdar AF
Int J Cancer; 2004 May; 109(5):786-92. PubMed ID: 14999791
[TBL] [Abstract][Full Text] [Related]
20. Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines.
Kim K; Takimoto R; Dicker DT; Chen Y; Gazitt Y; El-Deiry WS
Int J Oncol; 2001 Feb; 18(2):241-7. PubMed ID: 11172588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]